NABI SAYS CLOSES $500M LICENCE DEAL WITH GSK
Nabi said on Monday that it has closed an option and licence agreement for the smoking vaccine candidate NicVAx with GSK, AP reports.
The deal is potentially worth more than $500 million, including a $40 million upfront payment to Nabi and future milestone and royalty payments.
Nabi is developing NicVAx, which is intended to train the immune system to make antibodies that will attach themselves to nicotine. The goal is to keep the nicotine molecules from reaching the brain so people can quit smoking and not start again.